Trends in thiamine treatment patterns for Wernicke encephalopathy in Japan for 2010-2023: A nationwide descriptive study

This nationwide descriptive study of 7,856 Japanese patients with Wernicke encephalopathy from 2010 to 2023 reveals a significant shift toward high-dose thiamine treatment over time, yet highlights that despite early intervention and low in-hospital mortality, a substantial proportion of patients still experience functional impairment at discharge, underscoring the need for further research on optimal dosing and prevention.

The Gist

Imagine your brain is a high-performance car engine. Thiamine (Vitamin B1) is the premium fuel it needs to run smoothly. Without enough of this fuel, the engine starts to sputter, smoke, and eventually seize up. This condition is called Wernicke Encephalopathy. It's a medical emergency often caused by severe malnutrition or chronic alcohol use.

For years, doctors have been arguing about the best way to refuel this engine. Some say a small sip of fuel is enough; others scream for a massive firehose of it.

This new study from Japan is like a giant traffic report that looked at how doctors treated this "engine trouble" across the entire country over 13 years (2010–2023). Here is what they found, translated into everyday language:

1. The Great Shift in Fueling Strategy

For a long time, most doctors in Japan were giving patients a "low dose" of thiamine—like putting a single cup of premium fuel in a tank that needs a gallon.

• The Trend: Over the last decade, things changed. Doctors started listening to international guidelines that suggested "high doses" (a firehose approach).
• The Result: In 2010, only about 1 in 20 patients got the high dose. By 2023, nearly 1 in 2 patients were getting the high dose. The medical community is definitely trying to be more aggressive with the treatment.

2. The "Race Against Time"

One piece of good news: Doctors are acting fast.

• The Analogy: Imagine a fire alarm goes off. In this study, the "firefighters" (doctors) usually started spraying water (thiamine) the same day the patient arrived at the hospital. There was almost no delay.
• The Reality: Even with this lightning-fast response, the damage was often already done.

3. The Bitter Truth: Survival vs. Recovery

This is the most important part of the story.

• The Good News: The "death rate" is actually quite low (about 4%). Most people survive the immediate crisis.
• The Bad News: While they survive, many don't get their "engine" back to 100%.
  • Think of it like a car that survived a crash but now has a bent frame.
  • 56% of the patients left the hospital still needing help with basic daily tasks (like walking, eating, or dressing). They were alive, but their "functional engine" was still sputtering.

4. Why Did the "High Dose" Group Look Worse?

The researchers noticed something confusing: The group that got the most thiamine (the firehose group) actually seemed to have worse outcomes than the low-dose group.

• The Analogy: It's not that the firehose broke the car. It's that the doctors only turned on the firehose for the cars that were already on fire and smoking heavily.
• The Takeaway: Doctors gave high doses to the sickest patients. So, the high dose didn't cause the bad outcome; the severity of the illness did. We can't say for sure yet if the high dose is better than the low dose, because we haven't done a perfect scientific test to compare them directly.

5. The Big Picture: Prevention is Key

The study concludes that while we are getting better at treating this condition, we are still losing the battle for full recovery.

• The Metaphor: We are very good at putting out the fire once the house is burning, but we are bad at stopping the house from catching fire in the first place.
• The Solution: The authors say we need to focus on prevention. If we can give "fuel" (thiamine) to high-risk people before their engine seizes up, we might save them from the damage entirely.

Summary

• Doctors are trying harder: They are using bigger doses of Vitamin B1 more often.
• Speed matters: They are treating patients immediately.
• But it's not enough: Even with fast, high-dose treatment, more than half of the patients leave the hospital still struggling to take care of themselves.
• The Future: We need to figure out the perfect dose (not too little, not too much) and, more importantly, stop the disease from happening in the first place.

In short: We are fighting the fire better, but we need to learn how to stop the spark before it starts.

Technical Summary

1. Problem Statement

Wernicke encephalopathy (WE) is an acute, severe neurological disorder caused by thiamine (vitamin B1) deficiency. While European guidelines (e.g., EFNS 2010) recommend high-dose intravenous thiamine (200–500 mg three times daily) based on biological plausibility, robust clinical evidence supporting specific dosing regimens is limited.

• Knowledge Gaps: There is a scarcity of data on real-world thiamine dosing trends following the 2010 guidelines, particularly in Asian populations. Furthermore, data regarding functional outcomes (activities of daily living) at discharge and in-hospital mortality in Japan are lacking.
• Objective: The study aimed to clarify nationwide trends in thiamine administration patterns and evaluate clinical outcomes (mortality and functional status) for patients hospitalized with WE in Japan over a 13-year period.

2. Methodology

• Study Design: A nationwide retrospective cohort study.
• Data Source: The Japanese Diagnosis Procedure Combination (DPC) inpatient database, covering approximately 50% of all acute-care inpatients in Japan (over 1,000 hospitals).
• Study Period: July 2010 to March 2024.
• Population:
  • Inclusion Criteria: Patients aged ≥18 years with a primary or admission-precipitating diagnosis of WE (ICD-10 code: E51.2) who received intravenous thiamine for at least 2 consecutive days.
  • Exclusion Criteria: Repeat admissions (only the first was included), patients <18 years, and those not meeting the thiamine administration criteria.
  • Final Cohort: 7,856 patients.
• Key Variables:
  • Exposure: Initial intravenous thiamine dose, categorized based on the dose administered on the second day of therapy (to account for admission timing):
    • Low: ≤300 mg/day
    • Medium: 301–900 mg/day
    • High: >900 mg/day
  • Outcomes: In-hospital mortality, ICU admission, 30-day readmission, length of stay, total healthcare costs, and functional status at discharge measured by the Barthel Index (BI) and Japan Coma Scale (JCS).
• Statistical Analysis: Descriptive statistics were used to analyze trends over time (Cochran–Armitage trend test). An exploratory analysis compared baseline characteristics and outcomes across dose categories using Absolute Standardized Differences (ASD) to assess confounding.

3. Key Contributions

• First Nationwide Analysis in Japan: This is the first study to provide a comprehensive, nationwide overview of WE treatment patterns and outcomes in Japan.
• Longitudinal Trend Analysis: It tracks the evolution of thiamine dosing over 13 years, directly correlating real-world practice with the 2010 guideline recommendations.
• Functional Outcome Focus: Unlike many studies focusing solely on mortality, this research emphasizes the Barthel Index at discharge, highlighting the substantial burden of functional impairment even among survivors.
• Incidence Estimation: It provides an estimated annual incidence rate for WE in Japan, allowing for cross-national comparisons.

4. Key Results

• Treatment Trends:
  • A significant shift in dosing patterns was observed. The proportion of patients receiving high-dose thiamine (>900 mg/day) increased markedly from 5.4% in 2010 to 49.0% in 2023.
  • Conversely, low-dose therapy (≤300 mg/day) decreased from 83.0% to 37.9%.
  • The distribution of doses was bimodal, with peaks at 100 mg/day and 1,500 mg/day, suggesting a polarization between traditional low-dose practices and guideline-driven high-dose regimens.
• Incidence: The estimated annual incidence in 2023 was 1.28 per 100,000 person-years, comparable to rates reported in Spain and Switzerland.
• Clinical Outcomes:
  • Mortality: The in-hospital mortality rate was 3.8%, consistent with European studies (~5%).
  • Functional Impairment: Despite prompt treatment (median time to first administration: 0 days), 56.1% of patients were discharged with impaired activities of daily living (Barthel Index <90).
  • Length of Stay: Median hospitalization was 23 days (IQR: 12–41).
• Exploratory Analysis:
  • Patients receiving high-dose thiamine were more likely to be treated at teaching hospitals and high-volume centers.
  • The high-dose group presented with more severe symptoms on admission (higher JCS scores indicating worse consciousness).
  • Crucially, there were no significant differences in in-hospital mortality or readmission rates between dose groups. However, functional outcomes (JCS and BI at discharge) appeared worse in the high-dose group, likely due to confounding by indication (sicker patients receiving higher doses).

5. Significance and Implications

• Guideline Impact: The study confirms that international guidelines have successfully influenced clinical practice in Japan, driving a shift toward high-dose therapy. However, the persistence of low-dose regimens and the bimodal distribution indicate that consensus on the optimal dose is not yet universal.
• Clinical Burden: The high rate of functional impairment at discharge (56.1%) despite early treatment suggests that WE causes irreversible structural brain damage if not prevented. This underscores that primary prevention (e.g., prophylactic thiamine for high-risk groups) is critical, as post-diagnosis treatment may not fully reverse deficits.
• Need for Further Research: The lack of clear mortality or functional benefit in the high-dose group (after accounting for severity) highlights the need for robust, randomized controlled trials to determine the true efficacy of high-dose regimens.
• Policy: The findings support the continued push for standardized, high-dose protocols while emphasizing the urgent need for primary prevention strategies to reduce the incidence and long-term disability associated with WE.

Limitations Noted: The study relies on administrative claims data, which lacks detailed etiology (alcohol vs. non-alcohol), precise neurological signs, and pre-admission functional baselines. Additionally, the observational nature prevents causal inference regarding dose efficacy.